NTC SRL

NTC presents positive Phase II MIRAKLE study results for NTC014 eye drops, showing non-inferiority in microbiological eradication of bacterial conjunctivitis despite lower posology, with unexpected efficacy against resistant pathogens. NTC aims to finalize commercial partnering for NTC014 by end of 2025.